RespireRx Pharmaceuticals (OTCQB:RSPI) Inc said Chief Scientific Officer and Interim CEO Arnold Lippa was an invited speaker at the 2022 GRI Virtual Conference last month, where he discussed the potential use of AMPAkines for the treatment of certain disorders.
Lippa described the work that EndeavourRx, the company’s business unit focused on neuromodulators, has done to develop a novel class of low-impact AMPAkines that have shown positive results in human studies of target engagement, ADHD, cognition and respiration, the company said. The full presentation can be seen here.
AMPAkines have shown positive effects in animal models, including genetically modified mice created as models of certain genetic disorders. The mice displayed similar symptoms as patients with GRIA disorders, and AMPAkines were shown to deliver improvements in behavior, cognition and breathing.
READ: RespireRx Pharmaceuticals highlights experimental data suggesting its GABAkine KRM-II-81 could be game-changing for tinnitus patients
GRI disorders refer to a family of very rare mutations in the genes responsible for the construction of ionotropic glutamate receptor proteins that, when assembled and activated by glutamate, allow the transport of cations through the neuronal membrane and into the cell.
Patients with GRI disorders display a broad spectrum of symptoms, including cognitive deficits, delayed development, autism spectrum disorder behavioral patterns, hypotonia, respiratory difficulties and treatment-resistant seizures, the company said.
“It was an honor to speak at the CureGRIN Foundation conference and present data we have accumulated with our collaborators supporting the concept that disorders of the ionotropic glutamate complex might underly many of the symptoms of these orphan disorders and that AMPAkines under development might possibly be used in the treatment of patients with mutagenic alterations in AMPA glutamate receptors,” Lippa said in a statement. “We are very enthusiastic about continuing our association with the CureGRIN Foundation and collaborating with the researchers to whom they have introduced us.”
The CureGRIN Foundation, which put on the conference with GRIN Therapeutics, is a parent-led organization working to find treatments and cures for patients with GRI disorders.
RespireRx Pharmaceuticals (OTCQB:RSPI) is a biopharmaceutical company developing innovative and revolutionary treatments for disorders caused by the disruption of neuronal signaling, including obstructive sleep apnea, attention deficit hyperactivity disorder, epilepsy, chronic pain, and spinal cord injury.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel